Q3 2019 Investor Presentation
Key financial results
Q3 2019
Diversified revenue
by geography & by business
Revenue
Gross margin
Non-GAAP operating profit*
Non-GAAP net income*
$662.2M
+12% (+15% CC)
59.2%
+100 bps
$182.0M
+15%
$128.1M
Europe, Asia
and Other
35%
(3)%
$0.89
Non-GAAP EPS*
(3)%
Cash flow from operations
$139.6M
Free cash flow
$124.6M
ResMed adjusts for the impact of the amortization of acquired intangibles, deferred revenue fair value adjustment,
the impact of U.S. tax reform on income tax expense, acquisition-related expenses, and restructuring-related
expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items
to facilitate a more meaningful evaluation of current operating performance.
© 2019 ResMed I Q3 2019 Investor Presentation | 38
Masks and
Accessories
37%
OOH SaaS
12%
US, Canada
and Latin
America
65%
Devices
51%
ResMedView entire presentation